Brevan Howard Capital Management 13F: Cuts BSX Stake by $1.2M

Brevan Howard Trims Stake in Medical Device Maker

Brevan Howard Capital Management lowered its exposure to Boston Scientific Corporation NYSE:BSX by cutting its holdings during the period. According to a Form 13F regulatory filing with the Securities and Exchange Commission, the investment manager sold off a portion of its equity to leave a smaller footprint in the medical technology sector. Because 13F filings look backward, this report reflects holdings as of May 15, 2026, and may not represent the investor's current position today.

Details on the Share Reduction

The fund cut its position by a 14.5% margin, shedding 29,188 shares of the medical device maker. That reduction brought the institutional investor down to a total of 171,568 shares remaining in its portfolio, compared to 200,756 shares held prior to the adjustment. The leftover block of shares held an estimated value of roughly $7.31 million at the time of the report.

Stock Price Levels and Valuation

Shares of Boston Scientific change hands around $42.60 on Saturday, hovering near its 52-week low of $41.39 and far below its peak of $105.65 for the year. The company operates with a trailing price-to-earnings ratio of 17.87 and a forward P/E of 13.07, alongside a market value of roughly $63.97 billion. Because these filings capture a past snapshot, portfolio managers often rebalance based on broader market trends and asset allocation targets.

Wall Street Analyst Updates

Wall Street research firms have kept a steady stream of updates on the medical device provider, holding a consensus buy recommendation backed by 29 analyst opinions. On October 14, 2026, Truist Securities maintained its buy rating on the stock while adjusting its price target from $57.00 to $51.00. Earlier on October 7, 2026, Barclays initiated coverage with an equal-weight rating and a $48.00 price target. Citigroup also maintained a neutral rating on October 5, 2026, with a target of $48.00, following an earlier downgrade in September. Wells Fargo kept an equal-weight rating on September 24, 2026, with a $48.00 target.

Understanding the Company

Boston Scientific Corporation develops, manufactures, and markets medical devices used in interventional medical specialties around the globe. Its product lines support cardiovascular procedures, rhythm management, and urological treatments, helping doctors diagnose and manage complex patient conditions.

What to Watch at Boston Scientific Corporation

Investors tracking institutional moves will want to watch for the company's next earnings report scheduled for release on October 28, 2026. Future regulatory filings will also show whether Brevan Howard continues trimming or stabilizes its position in the healthcare firm.